Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/10/22
Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022GlobeNewsWire • 11/03/22
Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred StockGlobeNewsWire • 10/05/22
Journey Medical Corporation to Participate in Upcoming October 2022 Investor ConferencesGlobeNewsWire • 10/04/22
Fortress Biotech to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/08/22
Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular RosaceaGlobeNewsWire • 08/30/22
Fortress Biotech (FBIO) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/11/22
Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/11/22
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver TransplantationGlobeNewsWire • 08/11/22
Journey Medical Corporation (FBIO) CEO Claude Maraoui on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/10/22
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/09/22
Analysts Estimate Fortress Biotech (FBIO) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 08/08/22
Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United StatesGlobeNewsWire • 05/31/22
Fortress Biotech to Participate in Two Upcoming May 2022 Investor ConferencesGlobeNewsWire • 05/18/22
Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/12/22
Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/10/22
Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022GlobeNewsWire • 05/03/22
Fortress Biotech to Present at the 21st Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/07/22
Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022GlobeNewsWire • 04/01/22
Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/28/22
Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/23/22
Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics MeetingGlobeNewsWire • 03/21/22